Alnylam Pharmaceuticals, Inc. (ALNY): Price and Financial Metrics


Alnylam Pharmaceuticals, Inc. (ALNY): $135.89

0.19 (+0.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALNY to Watchlist
Sign Up

Industry: Biotech


Ranked

of 496

in industry

ALNY POWR Grades


  • ALNY scores best on the Value dimension, with a Value rank ahead of 64.74% of US stocks.
  • ALNY's strongest trending metric is Value; it's been moving up over the last 206 days.
  • ALNY's current lowest rank is in the Momentum metric (where it is better than 5.09% of US stocks).

ALNY Stock Summary

  • ALNY's price/sales ratio is 27.37; that's higher than the P/S ratio of 92.53% of US stocks.
  • With a year-over-year growth in debt of 70.1%, Alnylam Pharmaceuticals Inc's debt growth rate surpasses 87.83% of about US stocks.
  • Revenue growth over the past 12 months for Alnylam Pharmaceuticals Inc comes in at 99.68%, a number that bests 94.23% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ALNY, based on their financial statements, market capitalization, and price volatility, are EXAS, NICE, CHKP, HZNP, and NET.
  • ALNY's SEC filings can be seen here. And to visit Alnylam Pharmaceuticals Inc's official web site, go to www.alnylam.com.

ALNY Price Target

For more insight on analysts targets of ALNY, see our ALNY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $174.89 Average Broker Recommendation 1.64 (Moderate Buy)

ALNY Stock Price Chart Interactive Chart >

Price chart for ALNY

ALNY Price/Volume Stats

Current price $135.89 52-week high $178.41
Prev. close $135.70 52-week low $119.29
Day low $134.06 Volume 262,600
Day high $136.69 Avg. volume 635,861
50-day MA $138.10 Dividend yield N/A
200-day MA $139.67 Market Cap 15.97B

Alnylam Pharmaceuticals, Inc. (ALNY) Company Bio


Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company was founded in 2002 and is based in Cambridge, Massachusetts.


ALNY Latest News Stream


Event/Time News Detail
Loading, please wait...

ALNY Latest Social Stream


Loading social stream, please wait...

View Full ALNY Social Stream

Latest ALNY News From Around the Web

Below are the latest news stories about Alnylam Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

Dicerna A Buy On Long-Term Potential

Photo by libre de droit/iStock via Getty ImagesDicerna Pharmaceuticals (DRNA) specializes in RNAi (RNA interference) therapies. This has become a major field for pharmaceutical companies in the last few years and promises to be a value generator for this coming decade. I am updating my thesis because when I wrote...

William Meyers on Seeking Alpha | May 11, 2021

Evercore ISI Stick to Their Buy Rating for Alnylam Pharmaceuticals By Investing.com

Evercore ISI Stick to Their Buy Rating for Alnylam Pharmaceuticals

Investing.com | May 3, 2021

Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive early results on clinical outcome measures from the 12-month analysis of ILLUMINATE-A Phase 3 study of OXLUMO® (lumasiran), an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – for the treatment of primary hyperoxaluria type 1 (PH1). These data were presented at the American Society of Pediatric Nephrology (ASPN)/Pediatric Academic Societies (PAS) virtual meeting being held on April 30–May 4, 2021.

Yahoo | May 3, 2021

Alnylam's (ALNY) Q1 Loss Narrower Than Expected, Revenues Beat

Alnylam (ALNY) beat estimates for both earnings and revenues in the first quarter of 2021.

Yahoo | April 30, 2021

Alnylam Pharmaceuticals EPS misses by $0.24, beats on revenue

Alnylam Pharmaceuticals (ALNY): Q1 Non-GAAP EPS of -$1.64 misses by $0.24; GAAP EPS of -$1.71 beats by $0.06.Revenue of $177.57M (+78.5% Y/Y) beats by $9.07M.Press Release...

Seeking Alpha | April 29, 2021

Read More 'ALNY' Stories Here

ALNY Price Returns

1-mo -2.15%
3-mo -13.19%
6-mo 9.76%
1-year -6.20%
3-year 32.18%
5-year 153.20%
YTD 4.55%
2020 12.85%
2019 57.96%
2018 -42.61%
2017 239.34%
2016 -60.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9967 seconds.